1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy

 
• By Joseph Haas

The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours

Investors responded negatively to Sophiris Bio Inc.’s data release for its Phase IIb localized prostate cancer therapy topsalysin on June 25, as the report of one patient death among 11 who received a second dose of the intratumoral injection overshadowed solid clinical response data from the 38-person trial. San Diego-based Sophiris saw its shares finish trading down 40% at $2.24.

Topsalysin is a first-in-class, transmembrane pore-forming protein that is genetically modified to be activated only by

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D